Humanized and chimeric monoclonal antibodies to CD81

US10815306B2 · kind B2 · utility

Assignee

• The Board of Trustees of the Leland Stanford Junior University · US

Inventors

• Shoshana Levy · Stanford, US
• AURÉLIEN MARABELLE · Sceaux, FR
• Ranjani Rajapaksa · Mountain View, US
• Felipe Vences-Catalan · Stanford, US
• Chiung-Chi Kuo · Stanford, US
• Jie Liu · Houston, US
• Ronald Levy · Palo Alto, US

Key dates

• Filing date: Jun 14, 2017
• Grant date: Oct 27, 2020
• Expiry date: Jun 14, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/734
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Humanized or chimeric anti-CD81 (cluster of differentiation 81) monoclonal antibodies are provided. The antibodies bind to human CD81, and find use in various therapeutic methods, including without limitation the reduction or prevention of tumor metastasis. Further provided are heavy chain and light chain variable region sequences as well as associated complementarity-determining region (CDR) sequences.